卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌患者效果研究*

doi:10.3969/j.issn.1672-5069.2024.04.025

摘要/Abstract

摘要： 目的探讨应用卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌(PLC)患者的效果。方法 2018年8月～2021年8月我院诊治的晚期PLC患者62例,被随机分为对照组31例和观察组31例,分别给予阿帕替尼治疗或卡瑞利珠单抗联合阿帕替尼治疗3个疗程。使用流式细胞仪检测外周血T淋巴细胞亚群CD3⁺、CD4⁺、CD8⁺细胞百分比,计算CD4⁺/CD8⁺细胞比值,采用电化学发光法检测血清甲胎蛋白(AFP)、热休克蛋白90α(HSP90α)和癌胚抗原(CEA)水平。结果在治疗3个月末,观察组和对照组客观缓解率分别为58.1%和32.3%,差异有统计学意义(P<0.05);观察组外周血CD4⁺细胞百分比和CD4⁺/CD8⁺细胞比值分别为(38.3±2.6)%和(1.3±0.2),均显著高于对照组【分别为(34.5±2.9)%和(1.1±0.2),P<0.05】;观察组血清AFP、HSP90α和CEA水平分别为(143.6±26.5)μg/L、(93.2±22.4)ng/mL和(13.2±4.3)ng/mL,均显著低于对照组【分别为(204.5±29.6)μg/L、(129.1±23.5)ng/mL和(28.6±4.8)ng/mL,P<0.05】;经随访,观察组和对照组中位总生存期分别为14个月和10个月,差异有统计学意义(Log Rank x²=5.033,P=0.025)。结论卡瑞利珠单抗联合阿帕替尼治疗晚期PLC患者有一定的临床疗效,可延长患者生存时间。

关键词: 原发性肝癌, 晚期, 卡瑞利珠单抗, 阿帕替尼, 总生存期, 治疗

Abstract: Objective The aim of this study was to explore the efficacy of camrelizumab and apatinib combination in the treatment of patients with advanced primary liver cancer (PLC). Methods 62 patients with advanced PLC were enrolled in our hospital between August 2018 and August 2021, and were divided randomly into control group (n=31) and observation group (n=31), receiving apatinib or camrelizumab and apatinib combination therapy for three months. The percentages of peripheral blood T lymphocyte subsets were detected by flow cytometry, and serum alpha-fetoprotein (AFP), heat shock protein 90α (HSP90α) and carcinoembryonic antigen (CEA) levels were detected by electrochemiluminescence. Results At the end of 3 month treatment, the Objective remission rates in the observation and control group were 58.1% and 32.3%, respectively (P<0.05); the percentage of peripheral blood CD4⁺ cells and the ratio of CD4⁺/CD8⁺ cells in the observation group were (38.3±2.6)% and (1.3±0.2), both significantly higher than [(34.5±2.9)% and (1.1±0.2), P<0.05] in the control; serum AFP, HSP90α and CEA levels were (143.6±26.5)μg/L, (93.2±22.4)ng/mL and (13.2±4.3)ng/mL, all much lower than [(204.5±29.6)μg/L, (129.1±23.5)ng/mL and (28.6±4.8)ng/mL, respectively, P<0.05] in the control; the mean overall survivals in the two groups were 14 months and 10 months (Log Rank x²=5.033, P=0.025). Conclusion The combination of camrelizumab and apatinib therapy has a certain clinical efficacy in the treatment of patients with advanced PLC, which might slightly safely prolong the survival.

Key words: Hepatoma, Advanced, Camrelizumab, Apatinib, Overall survival, Therapy

王秀芝, 常金, 宋丹, 谭亭昭. 卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 591-594.

Wang Xiuzhi, Chang Jin, Song Dan, et al. Should the camrelizumab in combination with apatinib in the treatment of patients with advanced primary liver cancer benefit?[J]. Journal of Practical Hepatology, 2024, 27(4): 591-594.

参考文献

[1] Zou Z, Zhang Z, Lu C,et al. Comparison of time trends in the incidence of primary liver cancer between China and the United States: an age-period-cohort analysis of the Global Burden of Disease 2019. Chin Med J (Engl), 2022,135(17):2035-2042.
[2] Peng Z, Fan W, Zhu B,et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol, 2023,41(1):117-127.
[3] Qiao W, Wang Q, Hu C,et al. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. Front Immunol, 2022,13(1):1019772.
[4] Wu JY, Yin ZY, Bai YN,et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma, 2021,8(1):1233-1240.
[5] Zhou N, Zhang C, Liu D,et al. Apatinib in combination with s-1 as first-line treatment in patients with advanced metastatic gastric cancer: results from an open, exploratory, single-arm, phase ii trial. Oncologist, 2021,26(3):e374-e381.
[6] Xu J, Zhang Y, Jia R,et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res, 2019,25(2):515-523.
[7] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝脏病杂志,2015,23(5):321-327.
[8] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治的专家共识. 中华肝脏病杂志,2009,17(6):403-410.
[9] Eisenhauer EA, Therasse P, Bogaerts J,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009,45(2):228-247.
[10] Rumgay H, Arnold M, Ferlay J,et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol, 2022,77(6):1598-1606.
[11] 杜尚云,翁莉,武敏. TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究. 实用肝脏病杂志,2023,26(1):116-119.
[12] Qin S, Li Q, Gu S,et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol, 2021,6(7):559-568.
[13] Yukami H, Kawazoe A, Lin YT,et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res, 2022,28(16):3480-3488.
[14] Qin S, Ren Z, Meng Z,et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol, 2020,21(4):571-580.
[15] 徐泽宇,汪海岩,田园. 卡瑞利珠单抗联合白蛋白紫杉醇二线治疗晚期胃癌的疗效及安全性. 现代肿瘤医学,2023,31(1):130-134.
[16] 徐金发,宋文灿,郑中显,等. 国产细胞程序性死亡受体1抑制剂卡瑞利珠单抗联合阿帕替尼一线治疗中晚期原发性肝癌的疗效研究. 中国全科医学,2022,25(26):3258-3262.
[17] Xu J, Shen J, Gu S,et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase ii trial. Clin Cancer Res, 2021,27(4):1003-1011.
[18] Ju S, Zhou C, Hu J,et al. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer, 2022,22(1):335.
[19] Mei K, Qin S, Chen Z,et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer, 2021,9(3):e002191.
[20] Zeng Z, Jiang Y, Liu C,et al. Efficacy and biomarker exploration of camrelizumab combined with apatinib in the treatment of advanced primary liver cancer: a retrospective study. Anticancer Drugs, 2021,32(10):1093-1098.

卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌患者效果研究^*

Should the camrelizumab in combination with apatinib in the treatment of patients with advanced primary liver cancer benefit?

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈思彤, 卫小蝶, 韦新焕, 郭海清, 张晶. 代谢功能障碍相关脂肪性肝病诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 481-483.
[2]	柳雅立, 张晶. 儿童和青少年代谢相关脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 488-491.
[3]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[4]	张全乐, 赵丹, 李杰, 刘三香, 刘刚, 李亚. 富马酸替诺福韦与恩替卡韦挽救治疗拉米夫定耐药的HBeAg阴性慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 515-518.
[5]	薛李娜, 诸国兵, 吴琳霖, 杨小星. TAF治疗ETV经治的低病毒血症慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 519-522.
[6]	张丽, 陈雅雯, 盖琳, 邱红, 甄鑫, 常静霞. 乙型肝炎病毒/丙型肝炎病毒共同感染患者临床特征及其对抗病毒治疗应答反应研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 523-526.
[7]	蒋瑶, 仲伟明, 周俏怡, 邵宁, 吕冰, 孙舒. 吗替麦考酚酯治疗难治性自身免疫性肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 539-542.
[8]	赵维波, 王源, 孔令甲, 朱玉森, 岳宗柱, 商西单. 球囊压迫辅助下内镜硬化剂注射治疗乙型肝炎肝硬化并发食管静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 559-562.
[9]	艾孜江·艾买提, 阿布都西库尔·阿布都米吉提, 迪丽努尔·阿卜杜热合曼, 吴源泉. 骨髓间充质干细胞移植联合自拟中药治疗失代偿期肝硬化患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 567-570.
[10]	李维新, 索爱军, 王秀峰. 地佐辛联合丙泊酚靶控输注处理接受内镜下注射硬化剂治疗的乙型肝炎肝硬化并发食管静脉曲张破裂出血患者麻醉苏醒和镇痛效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 575-578.
[11]	鲍应军, 张媛, 顾俊鹏, 朱帝文, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 任伟新. TIPSS术使用组合支架与Viatorr支架治疗肝硬化并发门静脉高压症患者长期疗效比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 583-586.
[12]	黄英, 杨志勇, 罗明. 卡瑞利珠单抗联合仑伐替尼治疗晚期原发性肝癌患者疗效和安全性分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 595-598.
[13]	王正华, 王明达, 张晓谦. 超声造影诊断肝脏占位性病变良恶性效能分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 607-610.
[14]	杨丽花, 丁凌, 张玉明. PTBD联合体外辅助胆汁入肠治疗恶性梗阻性黄疸患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 619-622.
[15]	徐乾山, 徐彤, 金磊, 马多朵, 黄瑞, 曹禺彤. CT增强扫描评估肝血管瘤血供分型和肝动脉栓塞治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 627-630.